Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
20 earlier
Following the withdrawal of billions of dollars in investments from Boehringer Ingelheim and Eli Lilly, German lawmakers have proposed a clause to the country’s healthcare reforms set to take effect Jan. 1.
Original title: “Roche flags ‘final opportunity’ for Germany to reestablish as a reliable investment location”
Gilead Sciences has picked up a new inflammatory disease program from China’s PepStar Therapeutics to pair with the Phase 2 inflammatory bowel disease asset emvistegrast.
Original title: “Gilead shops in IL-23, inking $1.3B upfront I&I deal with China’s PepStar”
Invikafusp alfa, a first-in-class dual T cell agonist, showed an objective response in various types of cancer, particularly among patients who did not respond to previous checkpoint inhibitor therapy.
Original title: “ESMO 2026: Marengo's bispecific antibody shrinks 8 tumor types in Phase 2”
After cardiac safety signals led to a full clinical hold on Aardvark Therapeutics’ studies of ARD-101, the biotech conducted an additional safety study, in which no cardiac events were detected. Aardvark plans to resume testing the candidate next year.
Original title: “FDA uncages Aardvark’s Prader-Willi study after new data cleared safety concerns”
Following exits for its subsidiaries Electra Therapeutics and Vega Therapeutics, Star is now mining for a new drug prospect.
Original title: “Star adds $200M after spinout successes”
EMA’s Emergency Task Force (ETF) and the African Medicines Agency (AMA) have published a joint position paper to support the timely start of clinical trials for potential…
Original title: “AMA and EMA issue joint guidance on Ebola vaccine development”
Read twice and referred to the Committee on the Judiciary.
Original title: “S 1837: Law Enforcement Training for Mental Health Crisis Response Act of 2021”
Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.
Original title: “HR 3595: Law Enforcement Training for Mental Health Crisis Response Act of 2021”
remibrutinib versus teriflunomide in relapsing multiple sclerosis remodel 1 and remodel 2 two randomised phase 3 trials
Original title: “Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials.”